Company: LIMN
Filing Date: 2025-07-28
Form Type: S-1/A
Source: 0001410578-25-001518
Chunk: 105

Company: Liminatus Pharma, Inc.
Filing Date: 2025-07-28
Form: S-1/A
Chunk 105
---
 and the other events contemplated by the Business Combination Agreement. Unless otherwise indicated or the context otherwise requires, references to the “Combined Company” refer to ParentCo and its consolidated subsidiaries after giving effect to the Business Combination. The unaudited pro forma combined balance sheet as of March 31, 2025 combines the historical balance sheets of Iris, ParentCo, and Liminatus on a pro forma basis as if the Business Combination and the other events contemplated by the Business Combination Agreement had been consummated on March 31, 2025. The unaudited pro forma combined statement of operations for the three months ended March 31, 2025 and the year ended December 31, 2024, combines the historical statements of operations of Iris, Liminatus and ParentCo on a pro forma basis as if the Business Combination and the other events contemplated by the Business Combination Agreement had been consummated on January 1, 2024, the beginning of the earliest period presented. The unaudited pro forma combined balance sheet as of March 31, 2025 and unaudited pro forma combined statement of operations for the three months ended March 31, 2025 has been derived from and should be read in conjunction with the following:

The unaudited pro forma combined statement of operations for the year ended December 31, 2024 has been derived from and should be read in conjunction with the following:

The unaudited pro forma combined financial information should also be read together with the sections of the financial statements of Iris as of and for the three months ended March 31, 2025, the financial statements of Iris as of and for the year ended December 31, 2024, the financial statements of ParentCo as of and for the three months ended March 31, 2025, the financial statements of ParentCo as of and for the year ended December 31, 2024, the financial statements of Liminatus as of and for the three months ended March 31, 2025, the financial statements of Liminatus as of and for the year ended December 31, 2024 and the sections of this filing entitled “Iris’s

65

Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and “Liminatus’s Management’s Discussion and Analysis of Financial Condition and Results of Operations,” as well as other financial information included elsewhere in this filing. Business Combination Agreement On November 30, 2022, Iris entered into a Business Combination